Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B

Marcellin P., Lau G., Bonino F., Farci P., Hadziyannis S., Jin R., ...Daha Fazla

NEW ENGLAND JOURNAL OF MEDICINE, cilt.351, sa.12, ss.1206-1217, 2004 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 351 Sayı: 12
  • Basım Tarihi: 2004
  • Doi Numarası: 10.1056/nejmoa040431
  • Dergi Adı: NEW ENGLAND JOURNAL OF MEDICINE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1206-1217
  • Bursa Uludağ Üniversitesi Adresli: Evet

Özet

Background: Available treatments for hepatitis B e antigen (HBeAg)-negative chronic hepatitis B are associated with poor sustained responses. As a result, nucleoside and nucleotide analogues are typically continued indefinitely, a strategy associated with the risk of resistance and unknown long-term safety implications.